» Articles » PMID: 18289953

Establishing a Reference Range for Bone Turnover Markers in Young, Healthy Women

Overview
Journal Bone
Date 2008 Feb 22
PMID 18289953
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Biochemical markers of bone turnover (BTMs) are important in determining fracture risk in postmenopausal women; high levels being associated with increased risk. A proposed goal of anti-resorptive therapy is to reduce BTMs to the lower half of the reference range for healthy young pre-menopausal women. Our aims were a) to establish reference ranges for bone alkaline phosphatase (bone ALP), crosslinked C- and N-telopeptides of type I collagen (betaCTX, NTX), osteocalcin (OC) and procollagen type I N propeptide (PINP) in pre-menopausal women and b) to investigate the determinants of these BTMs.

Methods: BTMs were measured in peripheral blood and second morning void urine collected from 200 healthy pre-menopausal women ages 30 to 45 years. Each subject completed a short medical and lifestyle questionnaire.

Results: BTMs were higher before the age of 35 years than after it. BTMs were higher in women with low BMI (betaCTX and OC), low alcohol consumption (PINP), current smoking habit (bone ALP and NTX), and around time of ovulation (NTX).

Conclusions: We recommend that the age range 35 to 45 years should be used when establishing BTM reference ranges in women.

Citing Articles

Reference Intervals (RIs) of the Bone Turnover Markers (BTMs) in Children and Adolescents: A Proposal for Effective Use.

Brescia V, Lovero R, Fontana A, Zerlotin R, Colucci S, Grano M Biomedicines. 2025; 13(1).

PMID: 39857618 PMC: 11759837. DOI: 10.3390/biomedicines13010034.


Clinical use of bone markers: a challenge to variability.

Filella X, Guanabens N Adv Lab Med. 2024; 5(1):7-14.

PMID: 38634081 PMC: 11019881. DOI: 10.1515/almed-2023-0092.


.

Filella X, Guanabens N Adv Lab Med. 2024; 5(1):15-23.

PMID: 38634078 PMC: 11019885. DOI: 10.1515/almed-2023-0041.


Current knowledge of bone-derived factor osteocalcin: its role in the management and treatment of diabetes mellitus, osteoporosis, osteopetrosis and inflammatory joint diseases.

Martiniakova M, Biro R, Kovacova V, Babikova M, Zemanova N, Mondockova V J Mol Med (Berl). 2024; 102(4):435-452.

PMID: 38363329 PMC: 10963459. DOI: 10.1007/s00109-024-02418-8.


Effectiveness and Usefulness of Bone Turnover Marker in Osteoporosis Patients: A Multicenter Study in Korea.

Yoo J, Park S, Kim D, Ha J, Rhee Y, Hong N J Bone Metab. 2023; 30(4):311-317.

PMID: 38073264 PMC: 10721375. DOI: 10.11005/jbm.2023.30.4.311.